Talphera, Inc. Reveals Two Significant Abstracts for AKI & CRRT 2026 Conference Talphera, Inc. announces its two abstracts accepted for presentation at the AKI & CRRT 2026 conference in San Diego, focusing on innovative renal therapies.

Talphera, Inc. Reveals Two Significant Abstracts for AKI & CRRT 2026 Conference #United_States #San_Mateo #Talphera #Niyad #Nafamostat

Talphera Reports Strong 2025 Financial Results and Clinical Study Update Talphera, Inc. announces its fourth quarter and full year 2025 financial results, highlighting key developments in their clinical trials and company growth.

Talphera Reports Strong 2025 Financial Results and Clinical Study Update #United_States #San_Mateo #Talphera #Niyad #Nafamostat

Talphera Reports Third Quarter 2025 Financial Results and Corporate Developments Talphera, Inc. announces its financial results for Q3 2025, highlighting key developments, including a $17 million financing and NEPHRO clinical study progress.

Talphera Reports Third Quarter 2025 Financial Results and Corporate Developments #United_States #San_Mateo #Talphera #Niyad #CorMedix

Talphera Welcomes Joe Todisco to Its Board of Directors with Strategic Vision Talphera has announced the appointment of Joe Todisco to its Board of Directors, enhancing its pharmaceutical strategy and potential for innovations.

Talphera Welcomes Joe Todisco to Its Board of Directors with Strategic Vision #USA #San_Mateo #Talphera #Niyad #Joe_Todisco

Talphera Inc. Reaches Key Milestone in NEPHRO CRRT Trial with 17 Patient Enrollments Talphera, Inc. announced the successful enrollment of 17 patients in its pivotal NEPHRO CRRT clinical trial, nearing its goal toward completion by 2025.

Talphera Inc. Reaches Key Milestone in NEPHRO CRRT Trial with 17 Patient Enrollments #United_States #Talphera #Niyad #San_Mateo,_California #Nafamostat

Talphera Reports Q2 2025 Financial Results and Highlights Corporate Progress Talphera, Inc. shares its second quarter 2025 financial results, highlighting key advancements in clinical studies and corporate strategy.

Talphera Reports Q2 2025 Financial Results and Highlights Corporate Progress #USA #San_Mateo #Talphera #Niyad #NEPHRO_Study

Talphera, Inc. Reports Financial Results and Corporate Updates for Q1 2025 Talphera, Inc. reveals its financial performance for the first quarter of 2025, showcasing key developments and future plans for innovative therapies.

Talphera, Inc. Reports Financial Results and Corporate Updates for Q1 2025 #United_States #San_Mateo #Talphera #Niyad #Nafamostat

Talphera Reports on Financial Performance for 2024 and FDA Collaboration Talphera, Inc. shares its financial results for the fourth quarter of 2024, highlighting FDA changes in patient study size, funding, and corporate strategies.

Talphera Reports on Financial Performance for 2024 and FDA Collaboration #United_States #San_Mateo #FDA #Talphera #Niyad

Talphera's New FDA Agreement Promises Faster Enrollment for Critical Study Talphera, Inc. has secured a crucial FDA agreement for modifications to its NEPHRO CRRT study, aiming to expedite patient enrollment and enhance treatment approaches.

Talphera's New FDA Agreement Promises Faster Enrollment for Critical Study #United_States #San_Mateo #Talphera #Niyad #NEPHRO_CRRT